Vulcan Two Group PLC Signs ERP License Agreement to Scale ePharmacy Operations

• Operating expense: the annual subscription fee of £80,000, stepping up to £100,000 over the term, will hit the profit and loss account each year.
• Capitalised investment: the Company expects to capitalise the majority of the £765,000 implementation cost as an intangible asset. That means lower near-term P&L impact, with the cost recognised over time through amortisation. The exact useful life and amortisation profile are not disclosed.

Cash still leaves the building in 2026 for implementation and subscription. But capitalisation smooths the accounting charge, which can help reported profitability during the heavy lifting phase.

Execution: phased rollout to reduce disruption

A phased approach is sensible. Big-bang ERP launches often create headaches. Phasing lets Vulcan Two stabilise core modules, migrate data carefully and bring acquired businesses onto the platform in an orderly queue. Having a named ERP Director and a specialist consultancy adds accountability and experience, both essential when knitting together multiple companies.

The RNS indicates implementation across 2026. Exact go-live dates, sequence by function or business, and targeted benefits are not disclosed.

Positives worth calling out

• Strategic fit: the ERP underpins the buy-and-build thesis. One platform is how you get operating leverage, not just deal volume.
• Right-sized cost: a c.£765,000 implementation and £80,000-£100,000 annual fee look proportionate for a group integrating multiple businesses.
• Governance and delivery: a dedicated ERP Director plus a leading consultancy reduces execution risk.
• Data and control: better visibility and standardised processes should strengthen cash management, compliance and decision-making.

Things to watch and open questions

• Benefits case: the RNS does not quantify expected savings, margin uplift or working capital gains. Investors should watch for measurable outcomes once modules go live.
• Timeline risk: scope creep and data migration are the classic ERP pitfalls. Delays could push benefits to the right.
• Change management: process change across newly acquired teams is often the hardest part. Training and adoption will decide success.
• Accounting impacts: with most implementation spend capitalised, future amortisation will lift non-cash expenses. Useful life and amortisation timing are not disclosed.
• Provider not named: we know it is a global leader with AI-enabled functionality, but the specific platform is not disclosed.

Context with the £40 million raise and acquisitions

This ERP move follows Vulcan Two’s conditional £40 million raise to buy three ePharmacy businesses, as set out on 26 February 2026 and in the Admission Document on 27 February 2026. The Directors had already scoped requirements with the chosen provider and believe the platform suits the enlarged group. That sequence matters: lining up the systems plan before closing deals reduces the risk of running separate stacks for too long.

In short, the ERP is an enabling investment designed to turn acquired revenue into scalable, well-controlled cash flow. Without it, synergies tend to leak away in duplicated work and messy reporting.

My take for shareholders

This is a sensible, nuts-and-bolts announcement that supports the bigger story. The spend looks reasonable, the governance is in place, and a phased approach is the right call. The AI-heavy marketing language is fine, but the real prize is standardised processes and clean data across the group.

What I want next: a clear implementation roadmap with milestones, and – crucially – a benefits scorecard once key modules are live. Show the throughput improvements, month-end cycle time reduction, stock turns, order accuracy and headcount leverage. That is how investors will see the ERP converting into margin and cash.

Overall, positive. Execution remains the watchword, but this is the kind of infrastructure investment that can make a buy-and-build ePharmacy strategy actually work at scale.